Pharmacogenetics of carbamazepine

Pharmacogenetics of carbamazepine

Carbamazepine (CMZ) is a drug from the group of anticonvulsants, similar in chemical structure to tricyclic antidepressants. CMZ is widely used for mental disorders and neurological diseases. The lecture discusses the safety of CMZ in respect to personalized medicine, while considering the pharmacog...

Full description

Bibliographic Details
Main Authors:	N. A. Shnayder, E. N. Bochanova, D. V. Dmitrenko, R. F. Nasyrova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2020-01-01
Series:	Эпилепсия и пароксизмальные состояния
Subjects:	carbamazepine efficacy safety adverse drug reaction pharmacogenetics pharmacokinetics pharmacodynamics
Online Access:	https://www.epilepsia.su/jour/article/view/503

Similar Items

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility
by: Saldivar JS, et al.
Published: (2016-01-01)

Effects of Carbamazepine and Phenytoin on Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Lien Thi Ngo, et al.
Published: (2020-10-01)

Pharmacogenetic testing in schizophrenia in real clinical practice: before or after antipsychotic -induced adverse drug reactions development?
by: A. Abdyrakhmanova, et al.
Published: (2022-06-01)

Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01)

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics
by: Mercè Brunet, et al.
Published: (2022-08-01)

EFFICACY AND SAFETY OF ANTIEPILEPTIC DRUGS DURING PREGNANCY: PHARMACOGENETIC ASPECTS
by: E. A. Sоkоvа, et al.
Published: (2018-06-01)

Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions
by: Natalia A. Shnayder, et al.
Published: (2021-04-01)

Cutaneous reactions to carbamazepine in children with epilepsy
by: Asma Zamiri
Published: (2019-09-01)

Suspected hepatotoxicity and thrombocytopenia: Sodium valproate and carbamazepine
by: Siddhi Umarje, et al.
Published: (2018-01-01)

Genetic Risk Factors for Adverse Drug Reactions
by: D. A. Sychev, et al.
Published: (2022-04-01)

HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways
by: Funmilola Josephine Haukamp, et al.
Published: (2023-02-01)

Role of Pharmacogenetic Testing in the Risk and Safety Assessment of Valproates: The Ethnic Aspect (Review)
by: N. A. Shnayder, et al.
Published: (2024-07-01)

“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn
by: Caroline F. Samer, et al.
Published: (2017-04-01)

Chewable Versus Regular Carbamazepine
by: J Gordon Millichap
Published: (1992-07-01)

Corrigendum: Validation of single nucleotide variant assays for human leukocyte antigen haplotypes HLA-B*15:02 and HLA-A*31:01 across diverse ancestral backgrounds
by: Amanda Buchner, et al.
Published: (2022-08-01)

Validation of Single Nucleotide Variant Assays for Human Leukocyte Antigen Haplotypes HLA-B*15:02 and HLA-A*31:01 Across Diverse Ancestral Backgrounds
by: Amanda Buchner, et al.
Published: (2021-07-01)

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
by: Dawed AY, et al.
Published: (2016-04-01)

Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review
by: Emiliene B. Tata, et al.
Published: (2020-08-01)

Nanomedicine: pharmacological perspectives
by: Bhattacharya Santanu, et al.
Published: (2012-06-01)

Developments in pharmacogenetics, pharmacogenomics, and personalized medicine
by: Francisco Abad-Santos, et al.
Published: (2024-02-01)

Analysis of adverse reactions with phenytoin and carbamazepine in tertiary care hospital – A retrospective study
by: Syed Arshaduddin Ahmed1 , Mohammed Abid Ali2 , T S Usha Sree3 , Margaret Viola4 , Shaima Zafer Khan 5
Published: (2019-04-01)

The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
by: Gwendolin S. Simper, et al.
Published: (2019-10-01)

A multi-center interventional study to assess pharmacokinetics, effectiveness, and tolerability of prolonged-release tacrolimus after pediatric kidney transplantation: study protocol for a prospective, open-label, randomized, two-phase, two-sequence, single dose, crossover, phase III b trial
by: Sinem Karaterzi, et al.
Published: (2024-02-01)

Genetic features of a patient may influence the efficacy and safety profile of a medicinal product
by: D. A. Sychev
Published: (2024-07-01)

Carbamazepine drug reaction involving high fevers during the COVID-19 era
by: Reuben Heyman-Kantor, MD, et al.
Published: (2021-09-01)

Pharmacokinetic profile of carbamazepine and its metabolites on Javanese and Chinese ethnics in Indonesia
by: Mulyadi Djojosaputro, et al.
Published: (2010-01-01)

A quick review of carbamazepine pharmacokinetics in epilepsy from 1953 to 2012
by: Zahra Tolou-Ghamari, et al.
Published: (2013-01-01)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023-09-01)

Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compounds
by: Mohammad S. Alavijeh, et al.
Published: (2010-01-01)

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
by: Ana García-Robles, et al.
Published: (2020-07-01)

Corrigendum: Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol
by: Ana García-Robles, et al.
Published: (2022-01-01)

Efficacy of Carbamazepine in treatment of bronchial asthma
by: Mohamed Shahat Badawy, et al.
Published: (2014-01-01)

Carbamazepine-induced reversible vitiligo
by: Luai M. Assaedi, MD, et al.
Published: (2022-08-01)

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
by: Jean-Marc Ferrero, et al.
Published: (2023-02-01)

JAK inhibitors: an evidence-based choice of the most appropriate molecule
by: Luca Antonioli, et al.
Published: (2024-10-01)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
by: Alkabbani W, et al.
Published: (2021-07-01)

Pharmacogenetics-Informed Pharmacometabolomics as an Innovative Approach to Assessing the Safety and Risk of Pharmacotherapy with Valproic Acid
by: N. A. Shnayder, et al.
Published: (2023-12-01)

Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters
by: Teresa Iannaccone, et al.
Published: (2021-03-01)

Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study
by: Mahmood Mahajna, et al.
Published: (2023-12-01)

Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials
by: Cindy Hoi Ting Yeung, et al.
Published: (2024-01-01)